The Canadian veterinary journal = La revue veterinaire canadienne · 2023
Comparative efficacy of modified-live and inactivated vaccines in boosting disease-sparing responses to bovine viral diarrhea virus challenge in neonatally mucosally primed weanling beef calves.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Erickson Nathan, Godson Dale, Gow Sheryl, Lacoste Stacey, Waldner Cheryl, Ellis John
Аннотация
OBJECTIVE: This study compares immune and clinical responses of bovine viral diarrhea virus (BVDV)-maternal antibody (MatAb)-positive beef calves primed with intranasal modified-live virus vaccine (MLV) and differentially boosted with a systemic MLV or an inactivated vaccine (KV).
ANIMAL: Eighteen commercial Black Angus steers.
PROCEDURE: Calves were mucosally primed at ~24 h of age with an MLV and boosted by injection of a MLV (IN-MLV) or inactivated vaccine (IN-KV) at an average age of 54 d. Challenge occurred at weaning with a virulent non-cytopathic BVDV-2 strain, 24515.
RESULTS: Clinically, the IN-KV group had a longer duration of fever, leukopenia, and viremia, whereas the IN-MLV group had greater BVDV Types-1 and -2 heterospecific antibody responses.
CONCLUSION: Altogether, these data indicated that systemic MLV boosting resulted in a more robust protection to BVDV Type-2 challenge at weaning.
CLINICAL RELEVANCE: Mucosal prime-boosting of neonatal calves provided protection against BVDV Type-2 challenge at weaning.
ANIMAL: Eighteen commercial Black Angus steers.
PROCEDURE: Calves were mucosally primed at ~24 h of age with an MLV and boosted by injection of a MLV (IN-MLV) or inactivated vaccine (IN-KV) at an average age of 54 d. Challenge occurred at weaning with a virulent non-cytopathic BVDV-2 strain, 24515.
RESULTS: Clinically, the IN-KV group had a longer duration of fever, leukopenia, and viremia, whereas the IN-MLV group had greater BVDV Types-1 and -2 heterospecific antibody responses.
CONCLUSION: Altogether, these data indicated that systemic MLV boosting resulted in a more robust protection to BVDV Type-2 challenge at weaning.
CLINICAL RELEVANCE: Mucosal prime-boosting of neonatal calves provided protection against BVDV Type-2 challenge at weaning.